top of page

3 small-cap biotechs get a boost

A stream of updates from small cap stocks pushed research-focused firms higher on Wednesday.

Imugene (ASX:IMU)

Imugene rose 19% on results of clinical trials, the company announced the Cohort Review Committee confirmed the Phase I clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx, will proceed to the third and final highest dose cohort.

Market Cap - $572m

Revenue - $0

NPAT (loss) - ($10.5m)

RECCE Pharmaceuticals (ASX:RCE)

Superbug fighter Recce Pharma announced a patient had shown positive results after being treated with its experimental anti-infective product for a sinusitis infection that had been resistant to other treatments.

Market Cap - $167m

Revenue - $0

NPAT (loss) - ($4.3m)

MGC Pharmaceuticals (ASX:MXC)

Cannabis drug developer MGC Pharma gained after its quarterly revealed it had a record quarter in March, banking $880,000 for its medicinal cannabis products.

Market Cap - $137m

Revenue - $2m

NPAT (loss) - ($19.3m)

bottom of page